Tuberculosis preventive treatment in a single medical center and evaluation of the results

Çakar,Beyhan; Demir,Nalan; Karnak,Demet; Özkara,Şeref

doi:10.3892/etm.2014.1988

December-2014 Volume 8 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December-2014 Volume 8 Issue 6

Full Size Image

Article

Tuberculosis preventive treatment in a single medical center and evaluation of the results

Authors:
- Beyhan Çakar
- Nalan Demir
- Demet Karnak
- Şeref Özkara
View Affiliations / Copyright

Affiliations: Ankara Tuberculosis Control Dispensary No. 7, Ankara 06100, Turkey, Department of Chest Diseases, Ankara University School of Medicine, Ankara 06100, Turkey, Department of Chest Diseases, Atatürk Chest Diseases and Chest Surgery Educational and Training Hospital, Ankara 06280, Turkey
Pages: 1874-1878
|
Published online on: September 22, 2014

https://doi.org/10.3892/etm.2014.1988
Expand metrics +

Abstract

The aim of the present study was to evaluate the application of tuberculosis preventive treatment (TB‑PT). Demographic data, indications and results for cases that received TB‑PT at the Ankara Tuberculosis Control Dispensary No. 7 between 2008 and 2011 were retrospectively evaluated. The ‘Prevention with Drugs’ registry at the dispensary was used. A total of 463 cases received TB‑PT, with the indications including close contact with an active TB case (44%), positive tuberculin skin test (TST) in a child <15 years‑old (25%) and immunosuppressive therapy (31%). The immunosuppressed group (n=144) were administered steroids (10%) or tumor necrosis factor (TNF)‑α inhibitors (90%). Indications of TST conversion and sequela lesions were not observed among the cases. The male/female ratio was 106/98 for cases with TB close contact, 61/54 for TST‑positive cases and 85/59 for immunosuppressed cases. The mean ages of these groups were 9±5.7, 9.5±3.8 and 38±14.9 years, respectively. TB‑PT was completed in 364 cases (78.6%), and the rate of discontinuation due to adverse effects was 1% for TB close contact and 2% for TST‑positive cases, but 5% for immunosuppressed cases. While the percentage of TB close contact cases receiving TB‑PT decreased during the four‑year study period, the percentage of cases with immunosuppression (in particular patients using TNF‑α inhibitors) increased. Among the studied cases, only two subjects developed active TB. The first case involved a 1.5‑year‑old female that had close contact exposure to TB from a parent, while the other case involved a 14‑year‑old TST‑positive male (induration size,16 mm). In conclusion, patients receiving TB‑PT should be monitored and/or followed‑up carefully to control any side‑effects from the treatment and development of active TB.

View Figures

View References

1	Migliori GB, Raviglione MC, Schaberg T, et al: Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J. 14:978–992. 1999. View Article : Google Scholar
2	Gokcay G: Tuberculin skin test. Thorax Books: Tuberculosis. Ozkara S and Kilicaslan Z: 11. AVES Publishing; Istanbul: pp. 206–217. 2010
3	Ozkara S, Aktas Z, Ozkan S and Ecevit H; T.R. Ministry of Health, Department of Struggle Against Tuberculosis. Reference Book for the Control of Tuberculosis in Turkey. Rekmay Press; Ankara: pp. 55–58. 2003
4	Menzies D, Al Jahdali H and Al Otaibi B: Recent developments in treatment of latent tuberculosis infection. Indian J Med Res. 133:257–266. 2011.PubMed/NCBI
5	Lobue P and Menzies D: Treatment of latent tuberculosis infection: An update. Respirology. 15:603–622. 2010. View Article : Google Scholar : PubMed/NCBI
6	Chee CB, Sester M, Zhang W and Lange C: Diagnosis and treatment of latent infection with Mycobacterium tuberculosis. Respirology. 18:205–216. 2013. View Article : Google Scholar
7	No authors listed. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society MMWR Recomm Rep. 49(RR-6): 1–51. 2000.PubMed/NCBI
8	Cohn DL: Treatment of latent tuberculosis infection: renewed opportunity for tuberculosis control. Clin Infect Dis. 31:120–124. 2000. View Article : Google Scholar : PubMed/NCBI
9	Bliven EE and Podewils LJ: The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. Int J Tuberc Lung Dis. 13:1054–1060. 2009.PubMed/NCBI
10	Dobler CC and Marks GB: Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic. PLoS One. 7:e489002012. View Article : Google Scholar : PubMed/NCBI
11	Goswami ND, Gadkowski LB, Piedrahita C, et al: Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health. 12:4682012. View Article : Google Scholar : PubMed/NCBI
12	Horsburgh CR Jr, Goldberg S, Bethel J, et al: Tuberculosis Epidemiologic Studies Consortium: Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 137:401–409. 2010. View Article : Google Scholar
13	Kwara A, Herold JS, Machan JT and Carter EJ: Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest. 133:862–868. 2008. View Article : Google Scholar : PubMed/NCBI
14	Anibarro L, Casas S, Paz-Esquete J, et al: Mycobacteria Study Group (GEIM) of Spanish Society of Clinical Microbiology and Infections Diseases (SEIMC): Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. Int J Tuberc Lung Dis. 14:701–707. 2010.
15	Kunst H and Khan KS: Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis. 14:1374–1381. 2010.PubMed/NCBI
16	Shieh FK, Snyder G, Horsburgh CR, et al: Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med. 174:717–721. 2006. View Article : Google Scholar : PubMed/NCBI
17	Young J, Edick T, Klee D and O’Connor ME: Successful treatment of pediatric latent tuberculosis infection in a community health center clinic. Pediatr Infect Dis J. 31:e147–e151. 2012. View Article : Google Scholar : PubMed/NCBI
18	Lardizabal A, Passannante M, Kojakali F, et al: Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 130:1712–1717. 2006. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Tuberculosis preventive treatment in a single medical center and evaluation of the results

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles